Skip to content

Gomdori Medical

Evidence-Based Medical Education by gomdori, MD

MENU
  • Home
  • Gastroenterology
  • Procedures
  • Critical Care
  • More Specialties
    • Cardiovascular Medicine
    • Respiratory Medicine
    • Nephrology & Renal Care
    • Hematology
    • Oncology
    • Endocrinology
    • Allergy & Immunology
    • Infectious Diseases
    • Rheumatology
  • Tools
  • About gomdori Medical
  • Conference News
  • Clinical Library
Home » Acute Kidney Injury (AKI) — Diagnosis and Management

Acute Kidney Injury (AKI) — Diagnosis and Management

Posted on April 1, 2026October 29, 2026 by Gomdori
gomdori Medical · Clinical Guideline
Acute Kidney Injury (AKI) — Diagnosis and Management
Clinical Guideline gomdorimedical.com
Home › Guidelines › Acute Kidney Injury (AKI) — Diagnosis and Management
gomdori Medical
Clinical Guideline

Acute Kidney Injury (AKI) — Diagnosis and Management

📅 April 1, 2026 ✍️ gomdori ⏱ 18 min read KDIGO Clinical Practice Guideline
Referenced Clinical Guidelines
KDIGO
Kidney Disease: Improving Global Outcomes
Global clinical practice guidelines in nephrology
NICE
National Institute for Health and Care Excellence
UK evidence-based clinical guidance
⚡ Executive Summary

Diagnose AKI using KDIGO criteria: serum creatinine rise ≥0.3 mg/dL within 48 hours, ≥1.5× baseline within 7 days, or urine output <0.5 mL/kg/hr for 6 hours. Immediate management centers on volume resuscitation with balanced crystalloids (Lactated Ringer or Plasmalyte) at 1–2 mL/kg/hr, discontinuation of all nephrotoxins (NSAIDs, aminoglycosides, iodinated contrast), and hemodynamic optimization targeting MAP ≥65 mmHg. Initiate renal replacement therapy for life-threatening hyperkalemia (K+ >6.5 mEq/L with ECG changes), refractory pulmonary edema, severe acidosis (pH <7.1), or uremic complications. Monitor creatinine trends every 6–12 hours, urine output hourly, and electrolytes every 4–6 hours in the acute phase.

🧪 eGFR & CKD Stage

CKD-EPI 2021 equation. Enter serum creatinine, age, sex.

G1
≥90
G2
60–89
G3
30–59
G4
15–29
G5
<15
eGFR
90
Stage
G1
Enter values to see interpretation.
10–15%
Hospital Incidence
50–60%
ICU AKI Incidence
20–25%
Stage 3 Mortality
15–30%
CKD Progression Rate
Contents
  1. Pathophysiology
    • Tubular injury cascade
    • Prerenal vs intrinsic mechanisms
  2. Diagnostic Protocol
    • KDIGO staging criteria
    • Novel biomarkers
  3. Treatment Algorithm
    • Volume resuscitation
    • RRT indications
  4. Monitoring & Surveillance
  5. Clinical Commentary
  6. Practice Insights
  7. FAQ
1

Pathophysiology

Acute kidney injury represents a sudden decline in glomerular filtration rate caused by ischemic, nephrotoxic, or obstructive insults that disrupt the tightly regulated balance between renal oxygen delivery and tubular oxygen consumption. The kidney receives 20–25% of cardiac output but distributes blood unevenly—the outer medulla operates at a baseline PaO2 of only 10–20 mmHg, making the S3 segment of the proximal tubule and the thick ascending limb of the loop of Henle exquisitely vulnerable to hypoperfusion.

Core Mechanism
Tubular epithelial cell injury from ischemia-reperfusion or direct nephrotoxin exposure, leading to loss of brush border integrity, cell detachment, and intraluminal cast formation that obstructs flow
Key Pathway
ATP depletion → cytoskeletal disruption → loss of cell polarity → Na+/K+-ATPase redistribution to apical membrane → tubuloglomerular feedback activation → afferent arteriolar vasoconstriction → GFR drop
Genetic Factors
APOL1 G1/G2 variants (3–4× AKI risk in African ancestry), polymorphisms in ACE, IL-6, and TNF-alpha genes modulate susceptibility; HLA-DRB1 alleles linked to drug-induced interstitial nephritis
Risk Factors
MODIFIABLE: nephrotoxin exposure (NSAIDs, aminoglycosides, contrast), volume depletion, hypotension | NON-MODIFIABLE: age >65, pre-existing CKD (eGFR <60), diabetes, heart failure, sepsis
Biomarkers
Serum creatinine (lags 24–48h behind injury), cystatin C (less muscle-mass dependent), NGAL (rises within 2h of injury, >150 ng/mL predicts AKI), KIM-1, TIMP-2 × IGFBP7 (NephroCheck ≥0.3 = high risk)

The pathophysiologic cascade begins with a hemodynamic or toxic insult that depletes intracellular ATP in tubular epithelial cells within minutes. Without ATP, the Na+/K+-ATPase pump fails, causing sodium to accumulate intracellularly and water to follow, producing cellular swelling. Simultaneously, calcium floods the cytoplasm through voltage-gated channels, activating phospholipases and proteases that degrade the cytoskeleton and cell membrane. Injured tubular cells lose polarity and detach from the basement membrane, forming obstructive casts with Tamm-Horsfall protein in the tubular lumen. These casts increase intratubular pressure, reducing the net filtration pressure across the glomerulus. In parallel, damaged tubular cells release damage-associated molecular patterns (DAMPs) that activate toll-like receptors on resident dendritic cells and macrophages, triggering a sterile inflammatory response. Neutrophil infiltration amplifies tissue damage through reactive oxygen species and proteolytic enzymes. The macula densa senses increased chloride delivery from dysfunctional upstream tubules and activates tubuloglomerular feedback, causing afferent arteriolar vasoconstriction that further reduces GFR. Endothelial injury in peritubular capillaries causes microvascular congestion, leukocyte adhesion, and extension of the outer medullary ischemic zone. Recovery depends on surviving tubular cells dedifferentiating, proliferating, and re-establishing a polarized monolayer—a process that takes days to weeks and may remain incomplete, leaving residual interstitial fibrosis that predisposes to CKD progression.

AKI Pathophysiology Cascade Flowchart showing the progression from renal insult through tubular injury, inflammation, and GFR decline to clinical AKI Renal Insult (Ischemia / Toxin / Sepsis) ATP Depletion + Ca2+ Overload Na+/K+-ATPase failure, cytoskeletal disruption Tubular Cell Detachment + Cast Formation Intraluminal obstruction, backleak of filtrate Sterile Inflammation DAMPs, TLR activation, neutrophil ROS Tubuloglomerular Feedback Afferent vasoconstriction, GFR drop Clinical AKI (Rising Cr, Oliguria)
Kidney + Nephron + AKI Sites of Injury Renal anatomy: Kidney + Nephron + AKI Sites of Injury Left Kidney Cortex Medulla Pelvis Right Kidney Ureter Kidney + Nephron + AKI Sites of Injury
Renal Anatomy + AKI Pathology
2

Diagnostic Protocol

Suspect AKI in any hospitalized patient with rising creatinine, declining urine output, or worsening volume status. The diagnostic approach begins with establishing baseline creatinine (use the lowest value in the prior 3 months, or estimate from the MDRD equation if unavailable), classifying the AKI stage, then systematically differentiating prerenal, intrinsic, and postrenal etiologies. A focused history should assess recent nephrotoxin exposure (NSAIDs, aminoglycosides, contrast dye, ACE inhibitors), volume status changes, sepsis risk factors, and urinary symptoms suggesting obstruction. Physical examination focuses on jugular venous distension, peripheral edema, skin turgor, mucous membranes, and bladder distension.

KDIGO AKI Staging

KDIGO Acute Kidney Injury Staging System
StageSerum Creatinine CriteriaUrine Output CriteriaClinical Action
Stage 1≥0.3 mg/dL rise within 48h OR 1.5–1.9× baseline within 7 days<0.5 mL/kg/hr for 6–12 hoursDiscontinue nephrotoxins, optimize volume status, monitor Cr q12h, urinalysis with microscopy
Stage 22.0–2.9× baseline<0.5 mL/kg/hr for ≥12 hoursNephrology consult, renal-dose drug adjustments, consider renal ultrasound, strict I/O
Stage 3≥3.0× baseline OR ≥4.0 mg/dL OR initiation of RRT<0.3 mL/kg/hr for ≥24h OR anuria for ≥12hICU transfer if not already, urgent nephrology, evaluate for RRT, continuous hemodynamic monitoring

Diagnostic Workup

Recommended tests with diagnostic performance
TestRationale / What It ShowsSensitivitySpecificity
Urine microscopy (sediment)Muddy brown granular casts = ATN; RBC casts = glomerulonephritis; WBC casts = interstitial nephritis; bland = prerenal80–85%85–90%
Fractional excretion of sodium (FENa)<1% suggests prerenal; >2% suggests intrinsic ATN. Unreliable with diuretics or CKD78%84%
FE Urea (FEUrea)<35% favors prerenal even on diuretics; >50% favors intrinsic injury85%82%
Renal ultrasoundRules out obstructive uropathy (hydronephrosis); assess kidney size (small = chronic); Doppler for renal artery stenosis90–98% (obstruction)78–85%
NGAL (serum/urine)Early biomarker rising within 2h of tubular injury; >150 ng/mL predicts AKI development 24–48h before creatinine rise76%82%
TIMP-2 × IGFBP7 (NephroCheck)Cell-cycle arrest markers; ≥0.3 = moderate risk, ≥2.0 = high risk for Stage 2–3 AKI within 12h89%50%
KDIGO AKI Staging Severity Chart Horizontal bar chart showing three KDIGO AKI stages with associated mortality rates and creatinine thresholds KDIGO AKI Staging — Severity & Mortality Stage 1 Cr ≥0.3 mg/dL rise or 1.5–1.9x baseline Mortality: 5–10% ~8% Stage 2 Cr 2.0–2.9x baseline Mortality: 12–18% ~15% Stage 3 Cr ≥3.0x baseline or ≥4.0 mg/dL or RRT initiation Mortality: 20–35% ~28% Bar width represents relative severity & mortality risk 15–30% of hospital AKI patients progress to CKD within 2 years Increasing Severity & Mortality Risk

Differential Diagnosis

Key conditions to differentiate by AKI etiology
ConditionDistinguishing FeatureKey Workup
Prerenal azotemiaBUN:Cr >20:1, FENa <1%, bland sediment, rapid response to volume resuscitation (Cr normalizes within 24–48h)FENa, FEUrea, fluid challenge response
Acute tubular necrosis (ATN)Muddy brown granular casts, FENa >2%, persistent AKI despite volume repletion, history of ischemia or nephrotoxinUrine microscopy, urine sodium >40 mEq/L
Acute interstitial nephritisWBC casts, urine eosinophils (>1%), rash + fever + eosinophilia triad (present in only 10–15%), temporal drug exposureUrine eosinophils, renal biopsy if diagnostic uncertainty
Obstructive uropathyBilateral hydronephrosis on ultrasound, sudden anuria, pelvic malignancy history, elevated postvoid residual >200 mLRenal ultrasound, CT without contrast if stone suspected
GlomerulonephritisRBC casts (pathognomonic), dysmorphic RBCs, proteinuria >3 g/day, hypocomplementemia, positive ANCA or anti-GBMComplement levels, ANCA, anti-GBM, renal biopsy
Hepatorenal syndromeCirrhosis + ascites, Cr rise with no structural kidney disease, urine Na <10 mEq/L, no response to albumin challengeUrine sodium, albumin challenge (1 g/kg/day × 2 days)
3

Treatment Algorithm

AKI management is primarily supportive, targeting the underlying etiology while preventing further renal injury. The treatment algorithm follows a stepwise approach: optimize perfusion and volume status, eliminate nephrotoxins, manage complications (hyperkalemia, acidosis, volume overload), and determine timing of renal replacement therapy. No pharmacologic agent has demonstrated efficacy in accelerating AKI recovery—low-dose dopamine, fenoldopam, and loop diuretics do not prevent or treat established AKI. Treatment success is measured by creatinine trajectory and urine output trends, not by any single lab value.

1
Step 1 — Volume Optimization & Nephrotoxin Removal

All AKI patients require immediate hemodynamic assessment. For volume-depleted patients, administer balanced crystalloids as first-line resuscitation. Avoid normal saline (0.9% NaCl) for large-volume resuscitation due to hyperchloremic acidosis risk. Discontinue ALL nephrotoxins immediately and hold RAAS inhibitors until creatinine stabilizes. Target MAP ≥65 mmHg—use vasopressors if hypotensive despite adequate volume.

Lactated Ringer or Plasmalyte: 1–2 mL/kg/hr IV balanced crystalloid (adjust to urine output and CVP) Grade A

Norepinephrine (if vasopressor needed): Norepinephrine 0.05–0.5 mcg/kg/min IV targeting MAP ≥65 mmHg

Stop: NSAIDs, aminoglycosides, ACEi/ARBs, iodinated contrast, metformin, vancomycin (recheck levels)

✓ ResponderCreatinine trending down and urine output ≥0.5 mL/kg/hr within 6–12h → continue supportive care, reinstate RAAS inhibitors once creatinine at baseline
✗ Non-ResponderNo Cr improvement or oliguria persists despite adequate volume and MAP ≥65 mmHg → likely intrinsic AKI, proceed to Step 2
2
Step 2 — Complication Management & Supportive Therapy

Once intrinsic AKI is established, management shifts to preventing and treating metabolic complications while awaiting tubular recovery. Hyperkalemia is the most immediately life-threatening complication. Volume overload requires diuretic therapy but diuretics do NOT improve AKI outcomes or accelerate recovery—they only manage fluid balance. Metabolic acidosis requires bicarbonate only when pH <7.1 or bicarbonate <15 mEq/L with hemodynamic instability.

Hyperkalemia (K+ >5.5 mEq/L): Calcium gluconate 10% 10 mL IV over 2–3 min (cardiac membrane stabilization)

Insulin-glucose shift: Regular insulin 10 units IV + D50W 50 mL IV (shifts K+ 0.5–1.0 mEq/L in 15–30 min)

Volume overload diuresis: Furosemide 40–80 mg IV bolus (double dose q2h if no response, max 200 mg/dose) Grade B

Acidosis correction: Sodium bicarbonate 150 mEq in 1L D5W at 150 mL/hr (for pH <7.1)

Sodium polystyrene sulfonate: Patiromer 8.4 g PO daily OR Sodium zirconium cyclosilicate 10 g PO TID × 48h then 10 g daily

✓ ResponderElectrolytes stabilized, urine output improving, no volume overload → continue monitoring, anticipate recovery in 7–21 days for ATN
✗ Non-ResponderRefractory hyperkalemia, worsening acidosis, or pulmonary edema despite maximal medical therapy → proceed to Step 3 (RRT)
3
Step 3 — Renal Replacement Therapy (RRT)

RRT is indicated for life-threatening complications refractory to medical management. The STARRT-AKI trial demonstrated no survival benefit of early RRT initiation (within 12h of Stage 3) compared with a watchful waiting strategy in the absence of absolute indications. Continuous RRT (CRRT) is preferred for hemodynamically unstable ICU patients, while intermittent hemodialysis (IHD) is appropriate for hemodynamically stable patients. KDIGO recommends delivering a minimum effluent dose of 20–25 mL/kg/hr for CRRT.

CRRT (CVVHDF preferred): CRRT effluent dose 25–30 mL/kg/hr (prescribe 25% above target to account for downtime) Grade A

IHD (for stable patients): IHD 3–4 sessions/week, Kt/V ≥1.2 per session, blood flow 200–300 mL/min

Anticoagulation for CRRT: Regional citrate anticoagulation (preferred) OR heparin 500–1000 units/hr IV (target aPTT 45–55s)

✓ ResponderUrine output recovering >500 mL/day, Cr trending down off RRT, electrolytes stable → trial off RRT, monitor for rebound
✗ Non-ResponderNo renal recovery after 4–6 weeks → evaluate for AKI-to-CKD transition, plan for chronic dialysis access (AV fistula), nephrology longitudinal follow-up
AKI Treatment Algorithm Decision tree showing stepwise AKI management from volume optimization through complication management to renal replacement therapy AKI Diagnosed (KDIGO) Step 1: Volume + Stop Nephrotoxins Response? Yes Continue supportive care No Step 2: Manage Complications Refractory? Yes Step 3: Initiate RRT No Monitor for recovery Absolute RRT Indications: K+ >6.5, pH <7.1, pulmonary edema, uremic encephalopathy/pericarditis
⛔ Absolute Contraindication
NSAIDs in any stage of AKI. Iodinated contrast without compelling indication and pre-hydration. Metformin when creatinine >1.5 mg/dL or eGFR <30 mL/min (risk of lactic acidosis).
⚠️ Relative Contraindication
ACE inhibitors/ARBs during active AKI (may worsen renal perfusion; hold and reinstate after recovery). Aminoglycosides in AKI (if essential, use once-daily dosing with extended interval monitoring). Gadolinium contrast in Stage 3 AKI (risk of nephrogenic systemic fibrosis if eGFR <15).

Special Populations

Dose adjustments and considerations for special populations in AKI
PopulationDrug / ConsiderationSpecific Recommendation
CKD BaselineAll nephrotoxinsCKD patients develop AKI at lower absolute Cr thresholds; baseline eGFR <30 lowers threshold for nephrology consult and RRT readiness; avoid contrast if eGFR <30
Hepatic ImpairmentHepatorenal syndromeChild-Pugh C: low threshold for terlipressin + albumin trial; avoid nephrotoxins; Cr unreliable (low muscle mass); use cystatin C for GFR estimation
Elderly (≥65)Volume resuscitationCautious fluid dosing (1 mL/kg/hr max) due to reduced cardiac reserve; monitor for pulmonary edema; sarcopenia causes lower baseline Cr (underestimates AKI severity)
PregnancyPreeclampsia, HELLPNormal pregnancy Cr is 0.4–0.6 mg/dL; Cr ≥0.9 may represent significant AKI; avoid ACEi/ARBs (teratogenic); magnesium sulfate safe; early OB and nephrology co-management
PediatricFluid resuscitationBolus 10–20 mL/kg isotonic crystalloid; neonatal AKI defined by Cr not declining postpartum or rising ≥0.3 mg/dL; pRIFLE criteria preferred over adult KDIGO for children

Drug Interactions

Clinically significant interactions requiring action in AKI
DrugInteracting AgentMechanismClinical EffectManagement
VancomycinPiperacillin-tazobactamSynergistic tubular toxicity; competition for OAT secretion increases vancomycin tubular exposure40–50% increased AKI risk vs vancomycin + cefepimeUse cefepime or meropenem instead of pip-tazo when combined with vancomycin
ACEi/ARBsNSAIDs + Diuretics"Triple whammy": NSAID blocks prostaglandin-mediated afferent dilation, diuretic reduces volume, ACEi blocks efferent constrictionSevere prerenal AKI, especially in elderly and CKD patientsAvoid triple combination; hold ACEi/ARB and NSAID in AKI; restart ACEi/ARB after recovery
MetforminIodinated contrastContrast-induced AKI impairs metformin clearance, causing drug accumulationLife-threatening lactic acidosis (mortality 30–50%)Hold metformin 48h before and after contrast; resume only when eGFR confirmed ≥30 mL/min
AminoglycosidesLoop diureticsDiuretic-induced volume depletion increases aminoglycoside tubular concentration; both are ototoxicIncreased nephrotoxicity and ototoxicity riskAvoid concurrent use; if essential, extend dosing interval, monitor drug levels and Cr daily
5
NNT
Balanced crystalloids vs normal saline to prevent one AKI event
8
NNH
Vancomycin + pip-tazo AKI risk per 100 treated patients

Stepwise approach

Adult acute kidney injury: diagnosis and management

Management starts immediately, alongside the work-up.

  1. 1

    1. Confirm and stage AKI (KDIGO)

    • Creatinine up ≥0.3 mg/dL in 48 h or ≥1.5× baseline in 7 days, or urine output <0.5 mL/kg/h for 6 h
    • Urgent nephrology: Stage 2–3, suspected GN, possible RRT
  2. 2

    2. Find the cause

    • Urine sediment: muddy brown casts = ATN; RBC casts = GN; WBC casts = interstitial nephritis
    • FENa <1% or, on diuretics, FEUrea <35% suggests prerenal
    • Possible obstruction: ultrasound, catheter; urology if upper-tract or not relieved
  3. 3

    3. Restore perfusion

    • Volume-depleted: lactated Ringer's or Plasma-Lyte by default; 0.9% saline in traumatic brain injury
    • Hypotensive, no longer fluid-responsive: norepinephrine to MAP ≥65 mmHg, not more fluid
  4. 4

    4. Remove nephrotoxins

    • Stop NSAIDs and metformin; hold ACEi/ARBs
    • Aminoglycosides only if essential
    • Adjust renally cleared drug doses at the first sign of AKI
  5. 5

    5. Treat complications

    • Hyperkalemia with ECG changes: IV calcium gluconate first
    • K+ >6.0 mEq/L: IV insulin with glucose, then monitor glucose
    • Fluid overload, not anuric: loop diuretic; diuretics and low-dose dopamine do not treat AKI
  6. 6

    6. Renal replacement therapy

    • Start for refractory hyperkalemia, acidosis or pulmonary edema, or uremic complications
    • Hemodynamically unstable or raised ICP: CRRT; otherwise intermittent hemodialysis
Summary of this article's pathway; doses are not shown. Sources: This article; KDIGO AKI 2012; NICE NG148; UKKA hyperkalaemia 2023; FDA furosemide label; Surviving Sepsis Campaign 2026
4

Monitoring & Surveillance

Monitoring intensity scales with AKI severity. Stage 1 patients require creatinine checks every 12 hours and strict intake-output documentation, while Stage 3 patients need hourly urine output measurement, continuous hemodynamic monitoring, and electrolyte panels every 4–6 hours. The most critical early indicator of AKI trajectory is the urine output trend within the first 6–12 hours of intervention. After hospital discharge, all AKI survivors require nephrology follow-up within 90 days to assess for CKD transition, as 15–30% develop chronic kidney disease within 2 years.

Acute Phase (q4–12h)
  • Serum creatinine (q6–12h depending on stage)
  • Urine output (hourly via Foley catheter)
  • Serum potassium (q4–6h if >5.0 mEq/L)
  • Serum bicarbonate / venous blood gas
  • Fluid balance (strict I/O every shift)
Daily (Inpatient)
  • BMP (Na, K, Cl, HCO3, BUN, Cr, Glucose, Ca)
  • Phosphorus and magnesium
  • Daily weight (fluid balance proxy)
  • Nephrotoxin reconciliation review
Post-Discharge (1–4 Weeks)
  • Serum creatinine (verify recovery to baseline)
  • Urinalysis with protein-to-creatinine ratio
  • Blood pressure check
  • Medication reconciliation (reinstate RAAS inhibitors if appropriate)
Long-Term (3–12 Months)
  • eGFR at 3 months (assess CKD transition)
  • Urine albumin-to-creatinine ratio (UACR)
  • Blood pressure and cardiovascular risk assessment
  • Nephrology follow-up at 90 days post-AKI

Response & Safety Parameters

Monitoring protocol — parameters, targets, and action thresholds
ParameterTarget / ThresholdFrequencyAction if Abnormal
Serum creatinineTrending toward baseline; rise >0.3 mg/dL/day = worseningq6–12h (acute), daily (recovery)If rising despite intervention → reassess volume status, nephrology consult, consider RRT
Urine output≥0.5 mL/kg/hr (target); <0.3 mL/kg/hr = criticalHourly (Foley), q6h shift totalsIf <0.5 mL/kg/hr × 6h despite volume → furosemide stress test (1.0–1.5 mg/kg IV); UO <200 mL/2h predicts Stage 3 progression
Serum potassium3.5–5.0 mEq/L; >6.0 mEq/L with ECG changes = emergentq4–6h if >5.0 mEq/LK+ 5.5–6.0 → kayexalate or patiromer; K+ >6.0 + ECG changes → calcium gluconate + insulin/glucose + consider RRT
Serum bicarbonate≥18 mEq/L; pH ≥7.2q6–12h if <20 mEq/LpH <7.1 or HCO3 <12 → sodium bicarbonate infusion; if refractory → RRT
Volume statusEuvolemia (CVP 8–12, no pulmonary edema, no orthostasis)q shift reassessmentOverloaded → furosemide; hypovolemic → balanced crystalloid bolus; refractory overload → ultrafiltration via RRT
5

Clinical Commentary

💎 Clinical Pearl
The furosemide stress test (FST) is the single best bedside predictor of AKI progression. Administer furosemide 1.0 mg/kg IV (1.5 mg/kg if previously on loop diuretics) and measure urine output over 2 hours. A response of less than 200 mL in 2 hours predicts progression to KDIGO Stage 3 with a sensitivity of 87% and specificity of 84%. This test identifies patients who will likely need RRT 24–48 hours before conventional creatinine-based criteria, allowing earlier vascular access planning and family discussions. Replace the diuresed volume with equal crystalloid to maintain euvolemia during the test.
💎 Clinical Pearl
Serum creatinine is a lagging indicator that underestimates AKI severity in three common populations: elderly patients with sarcopenia (low muscle mass produces less creatinine), cirrhotic patients (impaired hepatic creatine synthesis), and patients receiving large-volume resuscitation (dilutional effect). In these patients, a creatinine of 1.5 mg/dL may represent a 50% GFR decline rather than the 25% decline implied by the absolute number. Use cystatin C as a complementary biomarker when creatinine seems disproportionately low for the clinical picture, and always interpret creatinine in the context of urine output trends and volume status.
⚠️ Common Pitfall
Continuing vancomycin-piperacillin/tazobactam without daily reassessment is a leading cause of hospital-acquired AKI. This combination carries a 40–50% higher AKI risk than vancomycin plus cefepime or meropenem, driven by synergistic tubular toxicity. Many clinicians default to this empiric combination for broad coverage without reassessing at 48–72 hours when cultures return. Switch to a narrower regimen as soon as culture data permits, and if broad gram-negative coverage is still needed, substitute cefepime for piperacillin-tazobactam to reduce AKI risk while maintaining anti-pseudomonal activity.
⚠️ Common Pitfall
Using loop diuretics to "treat" or "prevent" AKI by forcing urine output is a persistent myth that leads to harm. Furosemide converts oliguric AKI to non-oliguric AKI, which simplifies volume management but does NOT improve renal recovery, reduce the need for RRT, or lower mortality. Worse, aggressive diuresis in a volume-depleted patient extends the ischemic insult and delays recovery. Diuretics should only be used for volume management in euvolemic or hypervolemic AKI patients, never as a renal protective strategy. The appropriate first response to oliguria is a volume status assessment, not a furosemide order.
🚨 High-Alert Drug Warning — Gadolinium Contrast
Gadolinium-based contrast agents are contraindicated in patients with AKI Stage 3 or eGFR <15 mL/min due to the risk of nephrogenic systemic fibrosis (NSF), an irreversible fibrotic condition affecting the skin, joints, and internal organs. If gadolinium MRI is absolutely necessary, use Group II agents (gadobutrol, gadoterate) which carry the lowest NSF risk, and plan immediate post-procedure dialysis within 2–3 hours if the patient is already on RRT. Monitor for skin thickening, joint contractures, and scleroderma-like changes for 2–4 weeks post-exposure.
🏥 When to Refer
Nephrology consultation (urgent): All KDIGO Stage 2–3 AKI, AKI of unknown etiology requiring renal biopsy, suspected glomerulonephritis (RBC casts, positive ANCA/anti-GBM), or any patient being considered for RRT.
ICU transfer: Stage 3 AKI with hemodynamic instability (MAP <65 despite vasopressors), refractory hyperkalemia (K+ >6.5 mEq/L with ECG changes not responding to medical therapy), or pulmonary edema requiring emergent ultrafiltration.
Urology consultation: Obstructive AKI requiring percutaneous nephrostomy or ureteral stenting when Foley catheter does not relieve obstruction.
Post-discharge nephrology follow-up: All AKI survivors within 90 days to assess CKD transition (eGFR and UACR); earlier if residual creatinine elevation >25% above pre-AKI baseline at discharge.
❓ Areas of Uncertainty
  • Optimal timing of RRT initiation in non-emergent AKI Stage 3 remains debated despite STARRT-AKI and IDEAL-ICU trials
  • Role of novel biomarkers (NGAL, KIM-1, TIMP-2/IGFBP7) in guiding treatment decisions versus prognosis alone is not established
  • Whether early reinstatement of RAAS inhibitors post-AKI improves or worsens long-term renal outcomes lacks randomized evidence
📋 Patient Summary

Your kidneys have temporarily lost some of their ability to filter waste and excess fluid from your blood. This condition is called acute kidney injury. The medical team is working to identify the cause—which may include dehydration, certain medications, or an infection—and is providing intravenous fluids, stopping medications that may be harmful to the kidneys, and closely monitoring your blood tests and urine output. Most patients recover kidney function within days to weeks, but follow-up blood tests after discharge are important to ensure full recovery. Your doctor may temporarily hold certain blood pressure medications and will advise when it is safe to restart them.

Practice Insights: AKI After STARRT-AKI, SMART, and the Permissive-Hypotension Pivot

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Fear of the creatinine number drives more decisions in AKI than the patient's volume status does, and across dialysis timing, fluid choice and hepatorenal syndrome, the preferred approach has been quietly rewritten by three landmark trials: STARRT-AKI (early-RRT does not help), SMART (balanced crystalloid beats normal saline), and CONFIRM (terlipressin reverses HRS). The biggest practical shift, though, is psychological: clinicians have learned to tolerate creatinine rise after initial resuscitation rather than chasing it with more fluid or earlier dialysis. Doing less in the right patient is now the harder skill than doing more, and that pivot has prevented more harm in the unit than any new drug.

Balanced crystalloid first; normal saline only for hyperkalemia

Since SMART showed reduced renal composite outcomes with balanced crystalloid versus normal saline, lactated Ringer's or Plasma-Lyte has been the default AKI resuscitation fluid. clinicians use normal saline only when serum K+ is greater than 5.5 (LR contains 4 mEq/L K+, though the practical impact is minimal). The hyperchloremic acidosis from large-volume normal saline causes renal vasoconstriction that worsens the very AKI you are trying to reverse. clinicians have not seen the chloride load in NS get the respect it deserves on most floors.

Tolerate creatinine rise after the first 30 mL/kg

The biggest change in experienced practice from STARRT-AKI and from years of watching post-resuscitation fluid harm: once clinicians have given 25-30 mL/kg of balanced crystalloid and the patient is no longer fluid-responsive by PLR or PPV, clinicians stop fluid. Experienced clinicians tolerate a creatinine peak of 3-4 with the patient on stable low-dose vasopressors. Forcing the creatinine down with more crystalloid produces pulmonary edema, gut edema, and worse renal recovery. Roughly 1 in 4 of the historically-fluid-overloaded AKI patients would have done better with vasopressor support and fluid restriction earlier.

POCUS-driven AKI workup at the bedside

clinicians use bedside ultrasound on every ICU AKI patient: renal arterial Resistive Index (RI greater than 0.7 suggests intrinsic injury rather than prerenal); IVC collapsibility for volume status; lung B-lines for occult pulmonary congestion; bladder scan to rule out obstruction in the elderly. POCUS turns a one-hour workup into a 10-minute one and avoids transport-related risk. In experienced hands, RI greater than 0.8 in a post-cardiac-surgery patient on vasopressors predicts non-resolving AKI better than any biomarker seasoned clinicians can send to the lab.

Terlipressin for HRS — finally, an answer

Before terlipressin's FDA approval in September 2022, the HRS-AKI regimen was norepinephrine plus albumin or midodrine-octreotide-albumin — neither of which experienced practitioners felt great about. Terlipressin 0.5-1 mg IV every 4-6 hours plus albumin 25 percent (1 g/kg day 1, then 20-40 g daily) has reversed creatinine in roughly 30-35 percent of the HRS-AKI patients, compared to about 15-17 percent with the older regimens. Monitor for ischemia (cardiac, mesenteric, peripheral) and respiratory failure (about 11 percent rate). Stop at day 4-7 if no improvement.

Anonymized Case: Post-CABG Day 2 Oligo-Anuric Patient with Volume Overload

A man in his late sixties post on-pump CABG day 2 was consulted to the treating clinicians for oliguria (10 mL/hr) and rising creatinine (0.9 baseline to 2.3) despite 4 L of crystalloid given by the surgical team for "fluid responsiveness." On exam he had bibasilar crackles, B-lines on lung POCUS, IVC plethoric and non-collapsing, RI on renal POCUS 0.8, and norepinephrine 0.2 mcg/kg/min. clinicians stopped further fluid administration, started a furosemide infusion at 5 mg/hr titrated to 10 mg/hr for net negative balance, added vasopressin 0.03 U/min for MAP support, and held all renally cleared medications. Cr peaked at 3.4 on day 4, then declined. No RRT was needed. By day 7 he was net 5 L negative, off vasopressors, with eGFR 52. Discharged day 9.

The takeaway: the team's instinct to treat AKI with more fluid was the exact opposite of what this volume-overloaded patient needed. POCUS-confirmed fluid intolerance plus PPV non-responsiveness rewrote the management plan. Tolerating a Cr peak of 3.4 while diuresing was the right call, not early RRT.

Four Protocol Deviations Experienced Clinicians Now Default To

  1. Balanced crystalloid (lactated Ringer's or Plasma-Lyte) as the AKI resuscitation fluid; normal saline only if K+ > 5.5. Per SMART trial outcomes, chloride-induced renal vasoconstriction from NS worsens AKI in the same patients you are trying to resuscitate.
  2. Stop crystalloid after 25-30 mL/kg if PLR, PPV, or IVC collapsibility no longer supports fluid responsiveness — even if hypotensive. Vasopressor support (NE then add vasopressin 0.03 U/min fixed) over additional fluid in this physiology. CVP is not an acceptable fluid-responsiveness marker.
  3. POCUS workup at the bedside for every ICU AKI consult. Renal RI > 0.7 = intrinsic injury; IVC for volume; lung B-lines for occult pulmonary congestion; bladder scan in elderly to exclude obstruction. POCUS replaces the 1-hour transport-to-imaging workup with a 10-minute bedside answer.
  4. Terlipressin (0.5-1 mg IV q4-6h) + albumin 25% as first-line for HRS-AKI; abandon early-RRT for non-emergent AKI Stage 3. Skip IV bicarbonate and NAC for contrast-AKI prophylaxis (PRESERVE trial showed no benefit) — isotonic crystalloid prehydration alone is the only intervention with demonstrated efficacy.
AKI bedside protocol: fluid responsiveness gate + RRT trigger map Two-panel diagram showing fluid responsiveness gating after initial resuscitation and the RRT initiation thresholds. AKI: Stop-Fluid Gate + When to RRT Panel A: Stop-Fluid Gate Step 1: Initial resuscitation 25-30 mL/kg balanced crystalloid (LR/Plasma-Lyte) Step 2: Reassess responsiveness • PLR with SV rise > 10% (echo/arterial) • PPV > 12% (ventilated, regular rhythm) Step 3: STOP FLUID if non-responsive → NE 0.05-0.5 mcg/kg/min, add vasopressin → Tolerate Cr peak 3-4 over volume overload POCUS at the bedside: • Renal RI > 0.7 = intrinsic injury • Lung B-lines + IVC plethoric = stop fluid Panel B: RRT Indications (AEIOU) Emergent (start regardless of stage): A — Acidosis (pH < 7.1 refractory) E — Electrolytes (K+ > 6.5 + ECG changes) I — Intoxication (dialyzable toxins) O — Overload (pulmonary edema refractory) U — Uremic complications (pericarditis, sz) Non-emergent AKI Stage 3: STARRT-AKI: watchful waiting OK → no benefit from early RRT initiation → continuous (CRRT) preferred if unstable HRS-AKI special protocol: Terlipressin 0.5-1mg IV q4-6h + albumin 25% 1 g/kg D1, then 20-40 g/d; stop D4-7 if no improve Contrast-AKI prevention: isotonic crystalloid prehydration only Skip NaHCO3 and N-acetylcysteine (PRESERVE trial — no benefit). Hold ACEi/ARB/NSAIDs/metformin/SGLT2i 24-48h pre-contrast.
7

Frequently Asked Questions

When should I initiate renal replacement therapy in AKI?
Initiate RRT for life-threatening indications regardless of stage: refractory hyperkalemia (K+ >6.5 mEq/L with ECG changes), severe metabolic acidosis (pH <7.1 unresponsive to bicarbonate), refractory volume overload causing pulmonary edema, and uremic complications (encephalopathy, pericarditis, bleeding). For non-emergent AKI Stage 3, the STARRT-AKI trial supports a watchful waiting strategy over early initiation, provided no absolute indications exist.
How do I differentiate prerenal AKI from intrinsic renal injury at the bedside?
Fractional excretion of sodium (FENa) below 1% strongly suggests prerenal etiology in oliguric patients not receiving diuretics. If the patient is on diuretics, use fractional excretion of urea (FEUrea) instead — a value below 35% favors prerenal physiology. Urine microscopy showing bland sediment supports prerenal AKI, whereas muddy brown granular casts indicate acute tubular necrosis. A BUN-to-creatinine ratio greater than 20:1 also suggests prerenal azotemia but is less specific.
Should I dose-adjust medications in AKI even before creatinine peaks?
Yes. Renal drug clearance drops before creatinine reaches its peak because creatinine is a lagging indicator of GFR decline. Adjust renally cleared drugs (vancomycin, aminoglycosides, enoxaparin, metformin, DOACs) at the first sign of AKI, not after creatinine stabilizes. Use measured or estimated creatinine clearance with the understanding that it overestimates true GFR during the rising creatinine phase. Pharmacist consultation for AKI-specific dosing is strongly recommended.
Which crystalloid should clinicians use for AKI volume resuscitation — normal saline or balanced crystalloid?
Use balanced crystalloid (lactated Ringer's or Plasma-Lyte) as the default resuscitation fluid in AKI. The SMART trial (2018, 15,802 ICU patients) showed balanced crystalloid reduced the composite of death, new RRT, or persistent renal dysfunction at 30 days compared to normal saline. The mechanism is avoidance of hyperchloremic metabolic acidosis and chloride-induced renal vasoconstriction that occur with large-volume normal saline. The only exception is hyperkalemic AKI, where clinicians prefer normal saline over LR because LR contains 4 mEq/L of potassium — though the practical impact on serum K+ is minimal.
How do I assess fluid responsiveness once a patient has received initial AKI resuscitation?
Static markers (central venous pressure, gross urine output trends) are unreliable for predicting fluid responsiveness after initial resuscitation. clinicians use dynamic measures: passive leg raise (PLR) with stroke volume increase of more than 10 percent on bedside echo or arterial waveform; pulse pressure variation (PPV) greater than 12 percent on mechanically ventilated patients in regular rhythm; inferior vena cava collapsibility index over 50 percent. If none of these support fluid responsiveness and the patient remains hypotensive, clinicians escalate vasopressors rather than continuing crystalloid. Continuing fluid resuscitation in a fluid-unresponsive patient causes pulmonary edema, gut edema, and worse renal outcomes.
What is the role of terlipressin in hepatorenal syndrome AKI?
Terlipressin (Terlivaz) was FDA-approved in September 2022 for hepatorenal syndrome with rapid reduction in renal function. Experienced clinicians now use terlipressin 0.5 to 1 mg IV every 4 to 6 hours plus albumin 25 percent 1 g/kg on day 1 then 20 to 40 g daily as first-line therapy for HRS-AKI. Pre-FDA-approval era, clinicians used norepinephrine plus albumin or midodrine-octreotide-albumin combinations; terlipressin outperforms both in CONFIRM trial reversal rates (32 percent vs 17 percent). Monitor for ischemic complications (cardiac, mesenteric, peripheral) and respiratory failure — about 11 percent rate in trials. Stop terlipressin if serum creatinine has not improved by day 4 to 7.
Should I give IV bicarbonate or N-acetylcysteine to prevent contrast-induced AKI?
No. The PRESERVE trial (2018, 4,993 patients at risk for CI-AKI) showed neither IV sodium bicarbonate nor oral N-acetylcysteine reduced contrast-associated AKI, death, dialysis, or persistent kidney impairment compared to isotonic saline alone. The only intervention with demonstrated benefit is isotonic crystalloid prehydration (1 mL/kg/hr for 6 to 12 hours before and after contrast in high-risk patients). Use iso-osmolar (iodixanol) or low-osmolar contrast at the lowest diagnostic dose. Pause ACE inhibitors, ARBs, NSAIDs, metformin, and SGLT2 inhibitors 24 to 48 hours before procedural contrast in CKD patients. Skip the bicarbonate-NAC ritual; it adds cost without benefit.
gomdori Medical — Acute Kidney Injury (AKI) — Diagnosis and Management
Last updated: April 2026 gomdorimedical.com
Related clinical topics
More in Nephrology & Renal Care
  • Pre-Renal Acute Kidney Injury: Recognition, FENa Workup, and Volume-Responsive Management
  • Acute Interstitial Nephritis: Diagnosis and Management
  • Acute Pyelonephritis: Diagnosis and Management
  • Diabetic Kidney Disease: Diagnosis, Risk Stratification, and Evidence-Based Management
  • ANCA-Associated Vasculitis: GPA, MPA, EGPA Diagnosis and Induction Therapy
  • Post-Renal AKI from Urinary Tract Obstruction: Recognition, Decompression, and Post-Obstructive Diuresis Management
Posted in Nephrology & Renal CareTagged acute kidney injury, AKI, creatinine, dialysis, KDIGO staging, nephrotoxin, oliguria, renal replacement therapy, serum creatinine, volume resuscitation

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

61 free tools

Endoscopy Findings Atlas · Explore endoscopic findings and diagnostic distinctions.

Health & clinical tools

Find personal records, research helpers and clinical references.

  • Personal Records & Visits11 tools
  • Measurements & Conversions3 tools
  • Research & Events11 tools
  • Clinical Scores & Tests16 tools
  • Medication & Treatment References14 tools
  • Screening & Procedures6 tools
Browse all 61 tools →

Clinical references are for qualified professionals. Check each tool’s scope and limitations.

Tools to try
  • AUDIT-C Alcohol Screening & Unit Calculator
  • Acute Pancreatitis Severity Calculator
  • Ascites SAAG & SBP Diagnostic Assistant
Support This Project
Help keep medical education free
Donate via PayPal

Recent Posts

  • Spontaneous Intracranial Hypotension: CSF Leak Localization, Epidural Blood Patch, and CT-Myelography-Guided Repair
  • ICU Glycemic Control: Insulin Infusion Targets, Hypoglycemia Avoidance, and Transition to Subcutaneous Therapy
  • Choledocholithiasis: CBD Stones Cholangitis Charcot Reynolds Pentad MRCP EUS ASGE High Intermediate Low Risk Stratification ERCP Sphincterotomy Stone Extraction Balloon Dilation Lithotripsy Laparoscopic Cholecystectomy Management
  • Multicentric Reticulohistiocytosis: Arthritis Mutilans Skin Papulonodules and Paraneoplastic Histiocytic Disease
  • VIPoma: Verner-Morrison WDHA Syndrome Pancreatic Neuroendocrine Tumor Octreotide Therapy and Surgical Resection

Categories

  • Allergy & Clinical Immunology
  • Cardiovascular Medicine
  • Clinical Nutrition
  • Clinical Pharmacology
  • Critical Care Medicine
  • Dermatology
  • Emergency Medicine
  • Endocrinology & Metabolism
  • Gastroenterology
  • General Surgery
  • Geriatric Medicine
  • Hematology & Blood Disorders
  • Infectious Diseases
  • Medical Genetics
  • Nephrology & Renal Care
  • Neurology
  • Obstetrics & Gynecology
  • Occupational & Environmental Medicine
  • Oncology & Cancer Care
  • Ophthalmology
  • Order Sets
  • Orthopedics & Sports Medicine
  • Otolaryngology
  • Pain Medicine
  • Palliative Care
  • Pediatrics
  • Procedures
  • Psychiatry
  • Radiology
  • Respiratory Medicine
  • Rheumatology
  • Sleep Medicine
  • Urology
  • Vaccines & Preventive Medicine

Medical Disclaimer

This content is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for clinical decision-making. The author assumes no liability for actions taken based on this content.

GM

Gomdori, MD

Gastroenterologist · Medical educator

A practising gastroenterologist in South Korea writing bedside-focused clinical education — guideline-derived, dose-precise, and aimed at the decision in front of you rather than the exam question.

Writes about

Gastroenterology & hepatologyEndoscopyGuideline appraisal

Editorial standard

  • Every figure is traced to a primary source and dated
  • Corrections are made on request — not quietly
  • Unverifiable data is omitted, never estimated
About the author Corrections

gomdori Medical

Evidence-based medical education by a practicing gastroenterologist in South Korea. Free clinical content for physicians, residents, and medical students.

Learn more →

Quick Links

  • Gastroenterology
  • Procedures
  • Critical Care
  • About
  • Medical Disclaimer

Contact

Corrections, topic requests, and feedback are always welcome.

gomdoridoctor@gmail.com

Support via PayPal

© 2026 gomdori Medical. All rights reserved.

Content is for educational purposes only and does not constitute medical advice. Full disclaimer

Built with clinical expertise & programmatic precision.

AboutToolsPrivacy PolicyTerms of UseEditorial PolicyDisclaimerContact
Free tools →

© 2026 Gomdori Medical. Educational content only — not professional advice. Figures are dated at the point of publication and change over time; verify against the original source before acting on them.

AboutToolsPrivacy PolicyTerms of UseDisclaimerContact
Free tools →

© 2026 Gomdori Medical. Educational content only — not professional advice. Figures are dated at the point of publication and change over time; verify against the original source before acting on them.

Copyright © 2026 Gomdori Medical – OnePress theme by FameThemes